European Union - English - EMA (European Medicines Agency)

betapharm arzneimittel gmbh - azacitidine - myelodysplastic syndromes; leukemia, myelomonocytic, chronic; leukemia, myeloid, acute - antineoplastic agents - azacitidine betapharm is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation (hsct) with:intermediate-2 and high-risk myelodysplastic syndromes (mds) according to the international prognostic scoring system (ipss),chronic myelomonocytic leukaemia (cmml) with 10 % to 29 % marrow blasts without myeloproliferative disorder,acute myeloid leukaemia (aml) with 20 % to 30 % blasts and multi-lineage dysplasia, according to world health organization (who) classification,aml with > 30 % marrow blasts according to the who classification.

Ireland - English - HPRA (Health Products Regulatory Authority)

betapharm arzneimittel gmbh - ambrisentan - film-coated tablet - 10 milligram(s) - other antihypertensives; ambrisentan

Ireland - English - HPRA (Health Products Regulatory Authority)

betapharm arzneimittel gmbh - ambrisentan - film-coated tablet - 5 milligram(s) - other antihypertensives; ambrisentan

Israel - English - Ministry of Health

a.l. medi-market ltd. - dexamethasone phosphate (as sodium) - solution for injection / infusion - dexamethasone phosphate (as sodium) 4 mg / 1 ml - dexamethasone - dexamethasone rompharm is indicated in the treatment of:• endocrine diseases such as nonsuppurative thyroiditis, hypercalcaemia associated with cancer and congenital adrenal hyperplasia.• allergy: severe or disabling allergic conditions resistant to conventional treatments, as in: bronchial asthma, contact or atopical dermatitis, seasonal or perennial allergic rhinitis, hypersensitivity reactions to drugs.• ophtalmic: serious inflammatory and allergic processes, acute and chronic, affecting the eyes, such as: iritis and iridocyclitis, chorioretinitis, choroiditis and diffuse posterior uveitis, optical neuritis, allergic conjunctivitis, allergic marginal corneal ulcers.• inflammatory bowel dis.: systemic treatment in exacerbations of ulcerative colitis and regional enteritis.• dermatological diseases (pemphigus, stevens johnson syndrome, exfoliative dermatitis, severe psoriasis and mycosis fungoides) • respiratory diseases (symptomatic sarcoidosis, berylliosis, loeffler's syndrome)• haematological: acquired )autoimmune( haemolytic anaemia, idiopathic thrombocytopenic purpura, pure red cell aplasia• nephrotic syndrome of the idioplathic type or that due to lupus erythematosus• cerebral edema caused by brain tumor, neurosurgery, brain abscess, bacterial meningitis• collagen diseases: active rheumatoid arthritis with severe progressive course, fast destructive remitting forms and / or extra-articular manifestations, juvenile idiopathic arthritis with severe systemic-onset form (still's disease) or locally with no control, rheumatic fever with carditis, dermatomyositis, polymyositis, sle, temporal arteritis.• infectious diseases: bacterial meningitis – adjunct to antibiotics in suspected pneumococcal meningitis and tb meningitis. severe infectious diseases with toxic states (eg tuberculosis, typhoid, brucellosis;. only with simultaneous anti-infective therapy)• fetal lung maturation• chemotherapy – associated nausea and vomiting• multiple myeloma – part of chemotherapy protocols (eg vad)• prevention and treatment of acute mountain sickness/hace

Singapore - English - HSA (Health Sciences Authority)

pharmline marketing pte. ltd. - orthopaedics - go-on® is indicated as a viscoelastic supplementation for synovial fluid in the knee. viscosupplementation is recommended in patients with normal weight or moderately overweight with symptomatic mild to moderate knee oa who are not sufficiently improved by nonpharmacological treatment and analgesics/ nsaids or are unable to take analgesics/ nsaids. the actions of the product are lubrication and mechanical support, and it is suited for treatment of the symptoms of osteoarthritis.

Australia - English - Department of Health (Therapeutic Goods Administration)

novapharm research (australia) pty ltd - 33162 - detergent, - to clean medical and dental instruments

Australia - English - Department of Health (Therapeutic Goods Administration)

novapharm research (australia) pty ltd - 33162 - detergent, - to clean medical and dental instruments

Australia - English - Department of Health (Therapeutic Goods Administration)

novapharm research (australia) pty ltd - 38713 - disinfectant, surgical instrument - medical instrument cleaners with prion deactivating claims

Australia - English - Department of Health (Therapeutic Goods Administration)

novapharm research (australia) pty ltd - 38713 - disinfectant, surgical instrument - medical instrument cleaners with prion deactivating claims

Australia - English - Department of Health (Therapeutic Goods Administration)

novapharm research (australia) pty ltd - 33956 - disinfectant, medical device, - medical instrument cleaners with prion deactivating claims